Denufosol tetrasodium
CAS: 318250-11-2
Ref. 3D-ND45968
1mg | 1.096,00 € | ||
2mg | 2.068,00 € | ||
5mg | 3.318,00 € | ||
10mg | 5.401,00 € | ||
500µg | 779,00 € |
Produktinformation
- 2'-Deoxycytidine P'''-5'-ester with uridine 5'-(pentahydrogen tetraphosphate) sodium saltUridine 5'-(pentahydrogen tetraphosphate)
- P'5'-ester 2'-deoxycytidineINS 37217[[(3S,5R)-5-(4-Amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyp
- dCp4U
- Ins-37217
- Uridine 5'-(pentahydrogen tetraphosphate) P'''--5'-ester with 2'-deoxycytidine tetrasodium salt
- tetrasodium [[[[(3S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate
- tetrasodium [[[[(2R,3S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-oxido-phosphoryl]oxy-oxido-phosphoryl]oxy-oxido-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl phosphate
A P2Y2 receptor agonist that has been studied in cystic fibrosis and retinal diseases such as retinal detachment. Denufosol was studied as an inhaled drug for cystic fibrosis, due to its ability to activate an alternative chloride channel and avoiding the defective CFTR chloride channel. This enhances hydration of the lung mucosa and improves mucociliary clearance. The drug did not progress from phase III clinical trials. Denufosol resulted in subretinal fluid reabsorption in in vivo model of retinal detachment.
Chemische Eigenschaften
Technische Anfrage zu: 3D-ND45968 Denufosol tetrasodium
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.